Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Neurovance, Inc. Company Profile

00:41 EDT 19th April 2014 | BioPortfolio

Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.


News Articles [6 Associated News Articles listed on BioPortfolio]

Neurovance closes $6.3M extension to its series A1 financing round to advance the development of EB-1020 SR

Neurovance, Inc. today announced that it has closed a $6.3 million extension to its series A1 financing round to further advance development of EB-1020 SR, a non-stimulant, for the treatment of all su...

Neurovance Closes $6.3M Financing to Support Further Development of EB-1020 SR in Adult ADHD

—Initiating Additional Study to Confirm Anticipated Reduced Abuse Potential— —EB-1020 SR Is a Non-Stimulant but with the Potential Efficacy Profile of a Stim...

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in...

Neurovance financial update

Mass. developer of ADHD drug gets $6.3M funding boost

Neurovance, a Cambridge, Mass.-based biotech company developing a treatment for attention deficit hyperactivity disorder, sec -More- 

Neurovance Says Interim Data from Phase 2a Pilot Study of EB-1020 SR Shows Stimulant-Like Efficacy, but with Lower Risk of Abuse, for Adult ADHD

—EB-1020 SR is a Norepinephrine & Dopamine-Preferring Triple Reuptake Inhibitor for All Subtypes of Adult Attention Deficit Hyperactivity Disorder (ADHD)— Neuro...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Neurovance Inc.

Neurovance is a neuroscience-focused, clinical-stage biopharmaceutical company that specializes in triple reuptake inhibitors specifically optimized for adult attention deficit hy...

Neurovance, Inc.

Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurov...

More Information about "Neurovance, Inc." on BioPortfolio

We have published hundreds of Neurovance, Inc. news stories on BioPortfolio along with dozens of Neurovance, Inc. Clinical Trials and PubMed Articles about Neurovance, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurovance, Inc. Companies in our database. You can also find out about relevant Neurovance, Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement